



NHS RightCare Commissioning for Value Focus Pack

Respiratory
April 2016

- Introduction: Welcome to your focus pack
- NHS RightCare
- Why act?
- Commissioning for Value
- Your most similar CCGs
- Your data
 - Pathways on a page
 - Spend and activity
 - Opportunities
 - Further analysis
- Next steps and actions
- Further support and information
- Useful links
- Annexes

Introduction: Welcome to your focus pack

3

Welcome to your focus pack on respiratory disease. The information contained in this pack is personalised for your CCG and should be used to help support local discussions and inform a more in-depth analysis around respiratory pathways. There is a page of useful links at the end and there is a video guide to the pack too.

Each of these focus packs provides detailed information on the opportunities to improve in the highest spending programmes previously covered by Commissioning for Value packs. They include a wider range of outcome measures and information on the most common procedures and diagnoses for the condition in question.

By using this information, together with local intelligence and reports such as your Joint Strategic Needs Assessment, your CCG will be able to ensure its plans focus on those opportunities which have the potential to provide the biggest improvements in health outcomes, resource allocation and reducing inequalities.

One of the main focuses for the Commissioning for Value series has always been reducing unwarranted variation in outcomes. NHS England, Public Health England and CCGs have legal duties under the Health and Social Care Act 2012 with regard to reducing health inequalities. Commissioners should continue to use these packs and supporting tools to drive local action to reduce inequalities in access to services and in the health outcomes achieved.

The primary objective for NHS RightCare is to maximise value:

- the value that the patient derives from their own care and treatment
- the value the whole population derives from the investment in their healthcare

The approach has been tested and proven successful in recent years in a number of different health economies. The programme focusses on improving population value including improving outcomes, quality, and releasing capacity and resources for future investment.

To build on the success and value of the RightCare programme, NHS England and Public Health England are taking forward the RightCare approach to ensure it becomes embedded in the new commissioning and public health agendas for the NHS. It is now referenced in the Mandate to NHS England, the NHS Planning Guidance and the CCG Improvement and Assessment Framework.

The RightCare programme includes the Commissioning for Value packs and tools, the NHS Atlas series and a number of casebooks. NHS England has committed significant funding to rolling out the RightCare approach to all CCGs over the next two years. Wave 1 has 65 CCGs and these are now receiving early support from one of ten RightCare Delivery Partners. The remainder of CCGs are in Wave 2 and will receive support from an expanded team of Delivery Partners later in 2016.

“What Commissioning for Value does is shine an honest light on what we are doing. The RightCare approach then gives us a methodology for quality improvement, led by clinicians. It not only improves quality but also makes best use of the taxpayers’ pound ensuring the NHS continues to be one of the best value health and care systems in the world.”

Professor Sir Bruce Keogh
National Medical Director, NHS England

“The data and evidence available through tools such as Commissioning for Value will help commissioners make the most important decisions in delivering concrete and sustainable clinical and financial benefits across the NHS. We expect that the roll-out of the RightCare programme will drive up the quality of care while contributing significantly to meeting the efficiency challenge set out in the Five Year Forward View.”

Paul Baumann
Chief Financial Officer, NHS England

“Long term respiratory conditions like asthma and COPD are a priority area for many CCGs. The RightCare approach and Commissioning for Value provide CCGs with the simple tools necessary to provide much needed improvement in the quality of care for respiratory patients.”

Professor Mike Morgan
National Clinical Director for Respiratory, NHS England



Commissioning for Value is a partnership between NHS England and Public Health England. The *Where to Look* packs produced in January 2016 support the first phase of the NHS RightCare approach.

The *Where to Look* packs begin with a review of indicative data to highlight the top priorities or opportunities for transformation and improvement for your CCG.

These focus packs help CCGs to begin work on phase two *What to Change* by using indicative data along a pathway to identify improvement opportunities.

Your most similar CCGs

7

Your CCG is compared to the 10 most demographically similar CCGs. This is used to identify realistic opportunities to improve health and healthcare for your population. The analysis in this pack is based on a comparison with your most similar CCGs which are:

- East Lancashire
- Leeds North
- South Tees
- Leeds South and East
- Stoke on Trent
- Calderdale
- Lincolnshire West
- North East Lincolnshire
- West Lancashire
- Tameside and Glossop

To help you understand more about how your most similar 10 CCGs are calculated, the Similar 10 Explorer Tool is available on the NHS England website. This tool allows you to view similarity across all the individual demographics used to calculate your most similar 10 CCGs. You can also customise your similar 10 cluster group by weighting towards a desired demographic factor.

In addition to the similar 10, there are CCG cluster groups which have been constructed using the same variables (eg deprivation) as the similar 10. This larger cluster group is used in the opportunity tables, represented by a green triangle. Your CCG is in the following cluster group:

- Areas with younger adults and university cities

This focus pack presents analysis of a wide range of indicators focussing on spend, activity, quality and outcomes. The indicators have been chosen with advice from national clinical leads and other key stakeholders.

The data in this pack are the latest available*. The charts identify the metadata for each indicator and the full metadata set will be available on the Commissioning for Value pages of the NHS England website shortly. Data quality has been assessed and only indicators which are sufficiently robust have been included in the pack.

The data are presented as an exploration, starting with the pathways on a page, then moving to elective and non-elective spend, admissions, prescribing and procedures.

Should you have any queries about the indicators or the data, please refer to the contact details on the 'further information and support' page at the end of this pack.


*As the spend indicators have been updated since the publication of the 2016 refreshed 'Where to look' packs, figures for spend rates and potential opportunities may differ slightly from those packs.

The indicators on the following pages are identical to the respiratory related 'pathways on a page' from the previous Commissioning for Value packs; however the spend data has been updated.

The intention of these pathways is not to provide a definitive view on priorities but to help commissioners explore potential opportunities. These help commissioners to understand how performance in one part of the pathway may affect outcomes further along the pathway. Each indicator is shown as the percentage difference from the average of your 10 most similar CCGs.


The indicators are colour coded to help you see if your CCG has 'better' (green) or 'worse' (red) values than your peers. This is not always clear-cut, so (blue) is used where it is not possible to make this judgement. For example low prevalence may reflect that a CCG truly does have fewer patients with a certain condition, but it may reflect that other CCGs have better processes in place to identify and record prevalence in primary care. **Blue indicators could show significant opportunities for improvement.**

Even where an indicator is green there may still be an opportunity to improve. The programme opportunity tables, starting on page 40, identify the opportunities that exist for your CCG to improve to a level which matches the average of the best five of your similar 10 CCG group. Please note: The variation from the average of the similar 10 CCGs is statistically significant for those indicators where the confidence intervals do not cross the 0% axis.



NICE Guidance:

<http://pathways.nice.org.uk/pathways/chronic-obstructive-pulmonary-disease>



NICE Guidance:

<http://pathways.nice.org.uk/pathways/asthma>

NHS RightCare CFV Respiratory focus pack

The intention of the following pages is to provide a more in-depth view of the spend and activity for the clinical areas included in this pack compared to your 10 most similar CCGs. The charts show the rate for your CCG (yellow bar) and best five comparator (blue bar) and also the absolute difference (The 'how different are we?' column).

They should be used to explore key lines of enquiry to identify potential opportunities for improvement. For example a CCG with a high rate of spend on non-elective admissions may want to look at the QOF indicator on those who have had a review in the last 12 months.


The opportunity tables, starting on page 40, identify the best CCG in your similar 10, who you may want to contact – either directly or through your Delivery Partner.

Prescribing and procedures groups and single interventions have been chosen to reflect highest spend. National Clinical Directors and other expert stakeholders have advised on the chemical groupings of drugs used to treat certain conditions within a pathway. Similarly they have advised on procedure grouping. Annex A gives details of those groupings.

For some indicators, the difference between the value for your CCG and the Best 5 is marked as Not Statistically Significant (NSS). This means that we cannot say with confidence (statistically defined as >95% confidence) that any difference between your CCG and the Best 5 is not simply due to chance. Values for these cases have been included in order to provide detailed information for use in considering whether to explore an area further.

Respiratory - Spend

13




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators


Respiratory - Spend on elective conditions

14



Respiratory - Spend on elective conditions continued

15




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - Spend on elective conditions continued


16



| 95% confidence intervals
NSS Not statistically significant*
 *Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - Spend on non-elective conditions

17




| 95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - Spend on non-elective conditions continued

18




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - Spend on non-elective conditions continued

19




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators


Respiratory - admissions - COPD

20



Respiratory - admissions - Asthma


21



┆ 95% confidence intervals
NSS Not statistically significant*
 *Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - admissions - Acute upper respiratory

22




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - admissions - Chronic upper respiratory

23




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - admissions - Acute lower respiratory

24




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - admissions - Chronic lower respiratory

25



95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - admissions - Influenza and pneumonia

26




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - admissions - Lung diseases due to external agents

27




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - admissions - Other respiratory diseases principally affecting the interstitium

28




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - admissions - Suppurative and necrotic conditions of lower respiratory tract

29




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - admissions - Other diseases of pleura

30




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - admissions - Other diseases of the respiratory system


31



┆ 95% confidence intervals
NSS Not statistically significant*
*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - Primary Care Prescribing Spend

32



Medicines Optimisation Dashboard: <https://www.england.nhs.uk/ourwork/pe/mo-dash/>

Innovation Scorecard: <https://www.england.nhs.uk/ourwork/innovation/innovation-scorecard/>


| 95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Respiratory - Primary Care Prescribing Spend continued


33



Medicines Optimisation Dashboard: <https://www.england.nhs.uk/ourwork/pe/mo-dash/>

Innovation Scorecard: <https://www.england.nhs.uk/ourwork/innovation/innovation-scorecard/>

95% confidence intervals
NSS Not statistically significant*
 *Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Obstructive Airways Disease - procedures

35




95% confidence intervals

NSS Not statistically significant*

*Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Obstructive Airways Disease - procedures continued

36




95% confidence intervals
NSS Not statistically significant*
 *Where an opportunity is 'NSS' CCGs can investigate further whether this reflects a true opportunity e.g. by looking at more than 1 year's data or triangulating with other indicators

Scatter Plot Analysis

37

The Commissioning for Value Explorer Tool allows the comparison of two indicators, the diagram below is an example. This is an invaluable tool to enable users to assess how one indicator relates to another. The similar 10 can be highlighted too. It is important to remember that correlations do not imply causation but the relationships can help target where to look.

<http://www.england.nhs.uk/resources/resources-for-ccgs/comm-for-value/>



The opportunity tables present all focus pack indicators for five aspects of the pathway.

• **Risk** • **Prevalence and detection** • **Service and quality** • **Spend** • **Outcomes**

The width of the spine chart shows the England range. Your CCG is benchmarked against its similar 10 group. The shaded area of the spine chart within the table shows the range for the similar 10 group. Where the CCG is highest or lowest compared with its similar 10 group it is shown as outside that group range. This has been done to clearly show where the CCG is in relation to the similar 10 and the England worst/highest and best/lowest values.

Opportunities have been calculated for all indicators apart from those that relate to recorded prevalence and some risk factors. Where an indicator can be clearly interpreted as worse or better the spine charts show the position of the CCG, the best five average, and the wider cluster best CCG. The opportunity is quantified where the CCG is worse in relation to the Best 5 average.

Where an indicator needs to be locally interpreted (for example elective spend) and the CCG is higher than the average of the 5 CCGs with the lowest values, the opportunity table shows the potential opportunity. By calculating the potential opportunity it is possible to answer the question “Is it worth investigating this further?” The Best 5 average and the cluster best are not shown on the spine chart for these indicators.


Opportunity Table – Interpretation

39



‡ The wider cluster group best CCG is not always in the similar 10. It is included to indicate a 'stretch' target. Your wider CCG cluster group is identified on slide 7.

* per 1,000 age/sex weighted population
** per 100,000 age/sex weighted population
*** per 1,000 ASTRO-PU weighted population



Please note: For smoking and physical inactivity opportunities are not presented due to difficulties calculating these, rather than because they need local interpretation.

* No opportunity is calculated for risk and reported prevalence indicators

Please refer to slide 39 for full guidance on interpretation of this table of opportunities

* per 1,000 age/sex weighted population
** per 100,000 age/sex weighted population
*** per 1,000 ASTRO-PU weighted population

		● CCG		◆ Best 5		▲ Best in Cluster			
		England Worst or Highest		England Best or Lowest		Best/Lowest 5 Opportunity		Similar 10 Best	
Indicator		CCG Value						Page	
COPD Prevalence (%)		2.0				NA*			
Reported to estimated prevalence of COPD (%)		63.6				1450 Pats.		West Lancashire p.50	
Asthma prevalence (%)		6.3				NA*			

* No opportunity is calculated for risk and reported prevalence indicators

Please refer to slide 39 for full guidance on interpretation of this table of opportunities

Respiratory Conditions - Opportunity table - Activity and quality

NHS Greater Preston CCG 42

* per 1,000 age/sex weighted population
 ** per 100,000 age/sex weighted population
 *** per 1,000 ASTRO-PU weighted population


Indicator	CCG Value	CCG England Worst or Highest	Best 5	Best in Cluster England Best or Lowest	Best/Lowest 5 Opportunity	Similar 10 Best	Page
OAD - day case admissions (**)	6.4				7 Adms.		
OAD - avg. length of stay - emergency (bed days)	6.8				866 Bed days		
Asthma - day case admissions (**)	15.7				9 Adms. (NSS)		
Asthma -avg. length of stay - emergency (bed days)	2.3				97 Bed days (NSS)		
Asthma - emergency admissions by children (**)	328.0				80 Adms.	North East Lincolnshire	p.51
Asthma - Number of emergency admissions by adults (**)	95.7				30 Adms.	Lincolnshire West	p.52
Acute upper respiratory - day case admissions (**)	68.2				91 Adms.		
Acute upper respiratory -avg. length of stay - emergency (bed days)	0.7				66 Bed days		
Chronic upper respiratory - day case admissions (**)	140.4				115 Adms.		
Chronic upper respiratory -avg. length of stay-emergency (bed days)	2.3				30 Bed days (NSS)		
Acute lower respiratory - day case admissions (**)	No Data				No Data		
Acute lower respiratory -avg. length of stay - emergency (bed days)	4.1						
Acute l.respiratory infections - child emergency admissions (**)	378.9				93 Adms.	North East Lincolnshire	p.53
Acute l. respiratory. infections - adult emergency admissions (**)	204.4				64 Adms.	Leeds North	p.54
Chronic lower respiratory - day case admissions (**)	41.5				64 Adms.		
Chronic lower respiratory -avg. length of stay-emergency (bed days)	5.1				818 Bed days		
Chronic lower respiratory -avg. length of stay -elective (bed days)	8.2				146 Bed days		
Influenza and pneumonia - day case admissions (**)	No Data				No Data		
Influenza and pneumonia -avg. length of stay - emergency (bed days)	10.0				411 Bed days (NSS)		

Please refer to slide 39 for full guidance on interpretation of this table of opportunities

Respiratory Conditions - Opportunity table - Activity and quality


NHS Greater Preston CCG 43

* per 1,000 age/sex weighted population
 ** per 100,000 age/sex weighted population
 *** per 1,000 ASTRO-PU weighted population



Please refer to slide 39 for full guidance on interpretation of this table of opportunities

* per 1,000 age/sex weighted population
** per 100,000 age/sex weighted population
*** per 1,000 ASTRO-PU weighted population



* No opportunity is calculated for exception rates

Please refer to slide 39 for full guidance on interpretation of this table of opportunities

Respiratory Conditions - Opportunity table - Spend

NHS Greater Preston CCG 45

* per 1,000 age/sex weighted population
 ** per 100,000 age/sex weighted population
 *** per 1,000 ASTRO-PU weighted population

Indicator	CCG Value	England Worst or Highest	CCG	Best 5	England Best or Lowest	Best/Lowest 5 Opportunity	Similar 10 Best	Page
Respiratory - Total (*)	35295					£1110k		
Respiratory - Elective (*)	6555					£473k		
Respiratory - Non-elective (*)	28700					£696k	Lincolnshire West	p.65
Obstructive Airways Disease - Elective (*)	305					£42k		
Obstructive Airways Disease- Non-elective spend (*)	4949					£74k (NSS)	Leeds North	p.66
Asthma - Elective (*)	147					£20k		
Asthma - Non-elective spend (*)	1305					£74k	Lincolnshire West	p.67
Acute upper respiratory - Elective (*)	838					£80k		
Acute upper respiratory - Non-elective (*)	1518					£169k	Leeds North	p.68
Chronic upper respiratory - Elective (*)	2279					£172k		
Chronic upper respiratory - Non-elective (*)	279					£19k	Leeds North	p.69
Acute lower respiratory - Elective (*)	46							
Acute lower respiratory - Non-elective (*)	3707					£128k	Leeds North	p.70
Chronic lower respiratory - Elective (*)	1031					£158k		
Chronic lower respiratory - Non-elective (*)	6915					£207k	Leeds North	p.71
Influenza and pneumonia - Elective (*)	144					£11k (NSS)		
Influenza and pneumonia - Non-elective (*)	10223					£47k (NSS)	Lincolnshire West	p.72
Lung diseases due to external agents - Elective (*)	29					£4k (NSS)		
Lung diseases due to external agents - Non-elective (*)	1795					£99k	South Tees	p.73
Other respiratory diseases - Elective (*)	109					£8k (NSS)		

Please refer to slide 39 for full guidance on interpretation of this table of opportunities

Respiratory Conditions - Opportunity table - Spend

NHS Greater Preston CCG 46

* per 1,000 age/sex weighted population
 ** per 100,000 age/sex weighted population
 *** per 1,000 ASTRO-PU weighted population

Indicator	CCG Value	England Worst or Highest	England Best or Lowest	Best/Lowest 5 Opportunity	Similar 10 Best	Page
Other respiratory diseases - Non-elective (*)	449			£36k	West Lancashire	p.74
Lower respiratory tract conditions - Elective (*)	94			£16k		
Lower respiratory tract conditions - Non-elective (*)	183			£1k (NSS)	Calderdale	p.75
Other diseases of pleura - Elective (*)	211					
Other diseases of pleura - Non-elective (*)	1133			£56k	Calderdale	p.76
Other diseases of the respiratory system - Elective (*)	1769			£192k		
Other diseases of the respiratory system - Non-elective (*)	2453			£194k	North East Lincolnshire	p.77
Obstructive Airways Disease - primary care prescribing spend (**)	6908			£173k		
Primary care prescribing spend - Asthma (***)	13591			£203k		
Prescribing spend - Beclomethasone (***)	2849			£166k		
Prescribing spend - Salbutamol (***)	1240			£24k		
Prescribing spend - Seretide (***)	6618					
Prescribing spend - Spiriva (***)	4136			£121k		
Prescribing spend - Symbicort (***)	5169			£540k		
Procedure - CT - Head (*)	1393					
Procedure - CT - Pulmonary arteries (*)	1144			£45k		
Procedure - CT Not elsewhere classified (*)	965					
Procedure - Non-invasive ventilation - Not elsewhere classified (*)	1933			£46k (NSS)		
Procedure - Transthoracic ECG (*)	1913			£226k		
Procedure - Bilateral tonsillectomy (*)	545					

Please refer to slide 39 for full guidance on interpretation of this table of opportunities

Respiratory Conditions - Opportunity table - Spend

NHS Greater Preston CCG 47

* per 1,000 age/sex weighted population
 ** per 100,000 age/sex weighted population
 *** per 1,000 ASTRO-PU weighted population

Indicator	CCG Value	<div> ● CCG ◆ Best 5 ▲ Best in Cluster </div> <div> England Worst or Highest England Best or Lowest </div>	Best/Lowest 5 Opportunity	Similar 10 Best	Page
Procedure - CT - Chest (*)	795		£73k		
Procedure - Tube drain insertion - pleural cavity (*)	443		£18k (NSS)		
Procedure - Catheterisation of bladder (*)	336		£22k (NSS)		
Procedure - Aspiration of pleural cavity (*)	367				
Procedure - Invasive ventilation (*)	493		£38k (NSS)		
Procedure - Septoplasty of nose Not elsewhere classified (*)	197				
Procedure - Endoscopy&lavage of lesion - I.respiratory tract (*)	609		£89k		
Procedure - Drainage of pleural cavity - Not elsewhere classified (*)	173		£2k (NSS)		

Please refer to slide 39 for full guidance on interpretation of this table of opportunities

Respiratory Conditions - Opportunity table - Outcomes

* per 1,000 age/sex weighted population
** per 100,000 age/sex weighted population
*** per 1,000 ASTRO-PU weighted population

Indicator	CCG Value	England Worst or Highest	CCG	Best 5	England Best or Lowest	Best in Cluster	Best/Lowest 5 Opportunity	Similar 10 Best	Page
Deaths at home (%)	20.1						55 Deaths	West Lancashire	p.78
<75 Mortality from bronchitis, emphysema and COPD (**)	18.3							Lincolnshire West	p.79
Mortality from asthma all yrs (**)	1.6							Greater Preston	p.80

Please refer to slide 39 for full guidance on interpretation of this table of opportunities

Further Analysis - Introduction

49

The following pages, starting on page 50 provide a further analysis of a range of indicators in the focus pack. The indicators selected are those where we have been able to assign a judgment on whether a lower or higher value is *better* e.g. lower value better for mortality, higher value better for case finding.

Top Chart:

The opportunity box from the spine chart is shown in the top right of the blue banner. The top chart shows the whole England distribution together with the highlighted similar 10 group (grey bars) and your CCG (yellow bar). The England average is shown by the dashed blue line. The England value and Best 5 average values are shown below this chart.

Bottom Chart:

Shows your CCG and the similar 10 group together with their indicator values. The best 5 CCG average is shown by a dark blue line.



The full indicator name, source and time period are shown at the bottom left.

The analysis presented in the following slides can be replicated for *all* indicators in the focus pack using the Commissioning for Value Focus Pack Tool. The tool is available on the Commissioning for Value website, the link is available on page 84.

Reported to estimated prevalence of COPD (%)

1450 Pats.

50





Definition: Chronic Obstructive Pulmonary Disease (COPD) (%) Reported to estimated prevalence: Disease Register and Population
 Source: Quality and Outcomes Framework (QoF), The Health and Social Care Information Centre, INHALE (Interactive Health Atlas for Lung conditions in England), Public Health England
 Year: 2014/15 (2011)

Asthma - Emergency admissions by children (per 100,000 pop.)

80 Adms.

51





Definition: Asthma - Number of emergency admissions by children per 100,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Asthma - Emergency admissions by adults (per 100,000 pop.)

30 Adms.

52




Definition: Asthma - Number of emergency admissions by adults per 100,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Acute lower respiratory infections - Emergency admissions by children (per 100,000 pop.)

93 Adms.

53




Definition: Acute lower respiratory infections - Number of emergency admissions by children per 100,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Acute lower respiratory infections - Emergency admissions by adults (per 100,000 pop.)

64 Adms.

54





Definition: Acute lower respiratory infections - Number of emergency admissions by adults per 100,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

COPD patients where diagnosis confirmed by spirometry (%)

122 Pats.

55



Definition: The percentage of patients with COPD (diagnosed on or after 1 April 2011) in whom the diagnosis has been confirmed by post bronchodilator spirometry between 3 months before and 12 months



Source: Quality and Outcomes Framework

Year: 2014/15

COPD patients with dyspnoea grade ≥ 3 with record of O2 sat value (%)

38 Pats.

56



Definition: COPD005: The percentage of patients with COPD and Medical Research Council dyspnoea grade ≥ 3 at any time in the preceding 12 months, with a record of oxygen saturation value within the preceding 12 months



Source: Quality and Outcomes Framework

Year: 2014/15

COPD patients who have had flu immunisation (%)

223 Pats.

57





Definition: COPD007: The percentage of patients with COPD who have had influenza immunisation in the preceding 1 August to 31 March
 Source: Quality and Outcomes Framework
 Year: 2014/15

COPD patients who have had a review and breathlessness assessment (%)

289 Pats.

58



Definition: The percentage of patients who have had a review, undertaken by a healthcare professional, including an assessment of breathlessness using the MRC dyspnoea score in the preceding 12 months.


Source: Quality and Outcomes Framework

Year: 2014/15

COPD patients with a record of FeV1 in the preceding 12 months (%)

485 Pats.

59





Definition: % of COPD patients with a record of FeV1 in the preceding 12 months
 Source: Quality and Outcomes Framework (QoF), The Health and Social Care Information Centre
 Year: 2014/15

Patients (8yrs+) with asthma with measures of variability or reversibility (%)

209 Pats.

60



Definition: % of patients aged 8 or over with asthma (diagnosed on or after 1 April 2006), on the register, with measures of variability or reversibility recorded between 3 months before or any time after diagnosis



Source: Quality and Outcomes Framework (QoF), The Health and Social Care Information Centre

Year: 2014/15

Asthma patients who have had a review (12 months) (%)

380 Pats.

61



Definition: The % of patients with COPD who have had a review, undertaken by a healthcare professional, including an assessment of breathlessness using the Medical Research Council dyspnoea scale in the preceding 12 months



Source: Quality and Outcomes Framework (QoF), The Health and Social Care Information Centre

Year: 2014/15

Emergency admission rate for children with asthma, 0-18yrs (per 100,000 pop.)

81 Adms.

62



Definition: Emergency admission rate for children with asthma per 100,000 population aged 0–18 years



Source: Hospital Episode statistics (HES) via Business Objects (Methods)

Year: 2014/15

Asthma patients, 14-19, where smoking status is recorded (%)

20 Pats. (NSS)

63



Definition: AST004: The percentage of patients with asthma aged 14 or over and who have not attained the age of 20, on the register, in whom there is a record of smoking status in the preceding 12 months


Source: Quality and Outcomes Framework

Year: 2014/15

Smokers- support and treatment offered (%)

383 Pats.

64



Definition:

SMOK005: The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months

Source:

Quality and Outcomes Framework, The Health and Social Care Information Centre



Year:

2014/15

Respiratory conditions - Total non-elective spend (£ per 1,000 pop.)

£696k

65





Definition: Respiratory - Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Obstructive Airways Disease- Non-elective spend (£ per 1,000 pop.)

£74k (NSS)

66



Definition: Spend on non-elective (emergency and other non-elective) admissions for Obstructive Airways Disease per 1,000 population



Source: NHS Business Services Authority NHS Prescription Services Information Services Portal

Year: 2014/15

Asthma - Non-elective spend (£ per 1,000 pop)

£74k

67





Definition: Asthma - Total Spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Acute upper respiratory - Non-elective spend (£ per 1,000 pop.)

£169k

68




Definition: Acute upper respiratory - Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Chronic upper respiratory - Non-elective spend (£ per 1,000 pop.)

£19k

69





Definition: Chronic upper respiratory- Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Acute lower respiratory - Non-elective spend (£ per 1,000 pop.)

£128k

70





Definition: Acute lower respiratory - Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Chronic lower respiratory - Non-elective spend (£ per 1,000 pop.)

£207k

71





Definition: Chronic lower respiratory - Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Influenza and pneumonia - Non-elective spend (£ per 1,000 pop.)

£47k (NSS)

72





Definition: Influenza and pneumonia - Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Lung diseases due to external agents - Non-elective spend (£ per 1,000 pop.)

£99k

73




Definition: Lung diseases due to external agents - Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Other respiratory diseases principally affecting the interstitium - Non-elective spend (£ per 1,000 pop.)

£36k

74





Definition: Other respiratory diseases principally affecting the interstitium - Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Suppurative and necrotic conditions of lower respiratory tract - Non-elective spend (£ per 1,000 pop.)

£1k (NSS)

75




Definition: Suppurative and necrotic conditions of lower respiratory tract - Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Other diseases of pleura - Non-elective spend (£ per 1,000 pop.)

£56k

76





Definition: Other diseases of pleura - Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Other diseases of the respiratory system - Non-elective spend (£ per 1,000 pop.)

£194k

77





Definition: Other diseases of the respiratory system - Total spend on non-elective admissions per 1,000 population
 Source: Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart)
 Year: 2014/15

Deaths at home (%)

55 Deaths


78



Definition: Home deaths, Persons, All Ages (%)
 Source: End of Life Care Profiles, Fingertips, Public Health England
 Year: 2013

<75 Mortality from bronchitis, emphysema and COPD (per 100,000 pop.)


79



Definition: Mortality from bronchitis and emphysema and COPD: Under 75 Directly age-standardised rates (DSR) per 100,000
Source: Primary Care Mortality Database, HSCIC
Year: 2011-13

Mortality from asthma all yrs (per 100,000 pop.)

80



Definition: Mortality from asthma: all age directly age-standardised rates (DSR) per 100,000 European Standard Population
 Source: Primary Care Mortality Database, HSCIC
 Year: 2011-13

Commissioners can take the following actions now:

- Identify the key opportunities for improvement within the pathways included in the neurology focus pack for your population and compare with current reform activity and improvement plans.
- Engage with clinicians and other local stakeholders, including public health teams in local authorities and commissioning support organisations and explore the opportunities along the pathways further using local data.
- Revisit the Commissioning for Value web pages regularly as new content, including updates to tools to support the use of the Commissioning for Value packs, is regularly added.
- Watch the focus pack videos, and explore other clinical resources.
- Always consider risk factor reduction (e.g. smoking prevalence) as an opportunity to improve population health and reduce disease prevalence.
- Discuss the opportunities highlighted in this pack as part of the STP planning process and consider STP wide action where appropriate.
- For Wave One CCGs, speak to your Delivery Partner about other practical steps for your locality.
- For Wave Two CCGs, start to identify and act to improve the opportunities highlighted.

The Commissioning for Value benchmarking tool, explorer tool, full details of all the data used, and links to other useful tools are available on the Commissioning for Value pages of the NHS England website.

The NHS RightCare website offers resources to support CCGs in adopting the Commissioning for Value approach. These include:

- Online videos and 'how to' guides
- Case studies with learning from other CCGs

If you have any questions or require any further information or support you can email the Commissioning for Value support team direct at: england.healthinvestmentnetwork@nhs.net

Further surgical resources available for review

83

There are further resources on key surgical pathways and data freely available at The Royal College of Surgeons The National Surgical Commissioning Centre.

All the resources listed below are freely available at the website available on page 84.

- 1. Commissioning guides:** have been developed through a NICE accredited process and outline the 'high value' care pathway for a particular surgical complaint. Further information on the development of the commissioning guides is available online. Guides related to respiratory conditions include: **Rhinosinusitis** and **Tonsillectomy**
- 2. Data tools linked to commissioning guides:** use Hospital Episode Statistics (HES). All the tools have been developed with input from a multidisciplinary guideline development group and clinical coders and the technical definitions and guidance on navigating the tools are available to download. The data within these tools should be used as a start of a conversation between commissioners and their providers, to examine possible areas for improved efficiency and quality improvement

The Quality dashboards and Procedure explorer tool (PET)

There are 30 separate quality dashboards which show quality indicators for surgical procedures commissioned by commissioners. The PET tool shows further detailed information on individual procedures.

Data tools for Rhinosinusitis and Tonsillectomy are:

- Recurrent Tonsillitis or its complications
- Sleep disordered breathing in children <16
- Rhinosinusitis



Commissioning for Value pages of the NHS England website:

<http://www.england.nhs.uk/resources/resources-for-ccgs/comm-for-value/>

Commissioning for Value Similar 10 Explorer Tool:

<https://www.england.nhs.uk/wp-content/uploads/2016/01/cfv-16-similar-10-explr-tool.xlsm>

Supporting videos for the CFV focus packs:

<https://www.youtube.com/playlist?list=PL6lQwMACXkj1e17bcMvaHuy1gd9XrZT92>

NHS RightCare website:

<http://www.rightcare.nhs.uk/index.php/commissioning-for-value/>

Royal College of Surgeons National Surgical Commissioning Centre: <http://www.rcseng.ac.uk/surgical-commissioning>

Annex A: Condition and drug groupings

Respiratory conditions

86

Programme Budget Code group	Programme Budget Category	Primary Diagnosis Code
Obstructive Airways Diseases	11A	N/A
Asthma	11B	N/A

Condition Group	Programme Budget Category	Primary Diagnosis Code
Acute upper respiratory infections	11A, 11B, 11X	J00X, J010, J011, J012, J013, J014, J018, J019, J020, J028, J029, J030, J038, J039, J040, J041, J042, J050, J051, J060, J068, J069
Chronic upper respiratory diseases	11A, 11B, 11X	J300, J301, J302, J303, J304, J310, J311, J312, J320, J321, J322, J323, J324, J328, J329, J330, J331, J338, J339, J340, J341, J342, J343, J348, J350, J351, J352, J353, J358, J359, J36X, J370, J371, J380, J381, J382, J383, J384, J385, J386, J387, J390, J391, J392, J393, J398, J399
Acute lower respiratory infections	11A, 11B, 11X	J200, J201, J202, J203, J204, J205, J206, J207, J208, J209, J210, J211, J218, J219, J22X
Chronic lower respiratory diseases	11A, 11B, 11X	J40X, J410, J411, J418, J42X, J430, J431, J432, J438, J439, J440, J441, J448, J449, J450, J451, J458, J459, J46X, J47X
Influenza and pneumonia	11A, 11B, 11X	J09X, J100, J101, J108, J110, J111, J118, J120, J121, J122, J123, J128, J129, J13X, J14X, J150, J151, J152, J153, J154, J155, J156, J157, J158, J159, J160, J168, J170, J171, J172, J173, J178, J180, J181, J182, J188, J189
Lung diseases due to external agents	11A, 11B, 11X	J60X, J61X, J620, J628, J630, J631, J632, J633, J634, J635, J638, J64X, J65X, J660, J661, J662, J668, J670, J671, J672, J673, J674, J675, J676, J677, J678, J679, J680, J681, J682, J683, J684, J688, J689, J690, J691, J698, J700, J701, J702, J703, J704, J708, J709
Other respiratory diseases principally affecting the interstitium	11A, 11B, 11X	J80X, J81X, J82X, J840, J841, J848, J849

Respiratory conditions continued

87

Condition Group	Programme Budget Category	Primary Diagnosis Code
Suppurative and necrotic conditions of lower respiratory tract	11A, 11B, 11X	J850, J851, J852, J853, J860, J869
Other diseases of pleura	11A, 11B, 11X	J90X, J91X, J920, J929, J930, J931, J938, J939, J940, J941, J942, J948, J949
Other diseases of the respiratory system	11A, 11B, 11X	A065, A150, A151, A152, A153, A154, A155, A156, A157, A158, A159, A160, A161, A162, A163, A164, A165, A167, A168, A169, A190, A191, A192, A198, A199, A212, A221, A310, A360, A361, A362, A370, A371, A378, A379, A420, A430, A481, A70X, B012, B052, B250, B334, B371, B380, B381, B382, B390, B391, B392, B400, B401, B402, B410, B420, B440, B441, B442, B450, B460, B583, B671, B873, G473, J950, J951, J952, J953, J954, J955, J958, J959, J960, J961, J969, J980, J981, J982, J983, J984, J985, J986, J988, J989, J990, J991, J998, Q300, Q301, Q302, Q303, Q308, Q309, Q310, Q311, Q312, Q313, Q314, Q315, Q318, Q319, Q320, Q321, Q322, Q323, Q324, Q330, Q331, Q332, Q333, Q334, Q335, Q336, Q338, Q339, Q340, Q341, Q348, Q349, R040, R041, R042, R048, R049, R05X, R060, R061, R062, R063, R064, R065, R066, R067, R068, R090, R091, R092, R093, R098, R840, R841, R842, R843, R845, R846, R847, R848, R849, R91X, R942, Z030, Z111, Z222, Z430, Z825, Z836, Z870, Z902, Z930, Z942, Z963, Z990, Z991

Respiratory procedures

88

High spend procedures mapped to Programme Budget Codes: 11A, 11B and 11X

OPCS Procedure Code	Full procedure description	Short name in focus packs
E852	Non-invasive ventilation NEC	Non-invasive ventilation - NEC
U051	Computed tomography of head	CT - Head
U212	Computed tomography NEC	CT NEC
U354	Computed tomography of pulmonary arteries	CT - Pulmonary arteries
U201	Transthoracic echocardiography	Transthoracic ECG
F341	Bilateral dissection tonsillectomy	Bilateral tonsillectomy
U071	Computed tomography of chest	CT - Chest
T124	Insertion of tube drain into pleural cavity	Tube drain insertion - pleural cavity
M479	Unspecified urethral catheterisation of bladder	Catheterisation of bladder
T123	Aspiration of pleural cavity	Aspiration of pleural cavity
E851	Invasive ventilation	Invasive ventilation
E036	Septoplasty of nose NEC	Septoplasty of nose NEC
E492	Diagnostic fiberoptic endoscopic examination of lower respiratory tract and lavage of lesion of lower respiratory tract	Endoscopy and lavage of lesion - lower respiratory tract
T122	Drainage of pleural cavity NEC	Drainage of pleural cavity - NEC

Condition drug groups	Chemical level drugs included
Beclomethasone	Beclometasone Dipropionate
Salbutamol	Salbutamol
Seretide	Fluticasone Propionate (Inh), Salmeterol
Spiriva	Tiotropium
Symbicort	Budesonide, Formoterol Fumarate

SUS SEM code definitions

90

Admission Method	Admission Method Description
11	11: Waiting list
12	12: Booked
13	13: Planned
21	21: Accident and emergency or dental casualty department of the health care provider
22	22: General practitioner: after a request for immediate admission has been made direct to a hospital provider, i.e. Not through a bed bureau, by a general practitioner or deputy
23	23: Bed bureau
24	24: Consultant clinic, of this or another health care provider
25	25: Admission via mental health crisis resolution team
28	28: Other means, examples are: admitted from the accident and emergency department of another provider where they had not been admitted; transfer of an admitted patient from another hospital provider in an emergency; baby born at home as intended
2A	2A: Accident and emergency department of another provider where the patient had not been admitted
2B	2B: Transfer of an admitted patient from another hospital provider in an emergency
2C	2C: Baby born at home as intended
2D	2D: Other emergency admission
31	31: Admitted ante-partum
32	32: Admitted post-partum
81	81: Transfer of any admitted patient from other hospital provider other than in an emergency
82	82: The birth of a baby in this health care provider
83	83: Baby born outside the health care provider except when born at home as intended.

Patient Classification	Patient Classification Description
1	1: Ordinary admission
2	2: Day case admission

Person Gender Code	Person Gender Description
1	1: Male
2	2: Female

Annex B: High-level metadata

Admissions spend indicators

92

Analysis	Elective/Non-elective spend analysis
Time Period	2014/15
Age Group	0 – 120
Admissions method	Elective - 11, 12, 13** Non-Elective - 21, 22, 23, 24, 25, 28, 2A, 2B, 2C, 2D, 31, 32, 81, 82, 83** [Total spend indicators includes all elective and non elective admissions method codes]
Patient Classification	Elective - 1, 2** Non-Elective – 1**
Sex	1, 2**
Coding scheme used	Programme Budget Category (PBC), ICD10 Primary Diagnosis Codes
Numerator	Total spend on elective/non-elective admissions based on PBC/condition
Numerator Source	Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart) http://www.hscic.gov.uk/sus
Denominator	Age/Sex Standardised Population. Rate= (Numerator/Denominator) * 1000

**See annex for SUS SEM Code definitions

Secondary User Services Extract Mart (SUS SEM) data is used.
Only patients with a mandatory tariff recorded have been selected.

The fields that were pulled from SUS SEM include:

- CCG code (based on the GP practice code)
- Sex (this field is used for age/sex standardisation)
- Age_Quinary (Age Band)
- Number of spells
- Net_SLA_Payment (the cost before MFF is applied)

The data does not include CCGs which were not found in the official list of CCGs across England.

Age_Quinary field is presented in 5-year age bands (0-4, 5-9, 10-14, etc.) including the “85+” age band for people aged 85 and over. This field is used for age/sex standardisation.

Number of spells field counts all the patients admitted to hospital for a procedure and discharged in the financial year 2014/15 and groups into each age band. [Patients admitted in 2014/15 but not discharged until 2015/16 will not count towards the spend. A small number of patients admitted in 2013/14 but not discharged until 2014/15 will count towards the spend for 2014/15.]

Net_SLA_Payment field is the cost before Market Forces Factor (MFF) is applied. This field gives spend on elective/non-elective admissions for all patients in the age band in 2014/15.

The number of elective/non-elective admissions were suppressed where it was less than or equal to 5 at CCG level.

Day case admissions indicators

93

Analysis	Day case admissions analysis
Time Period	2014/15
Age Group	0 – 120
Admissions method	11, 12, 13
Patient Classification	2
Sex	1, 2
Coding scheme used	Programme Budget Category (PBC), ICD10
Numerator	Number of day case admissions based on PBC/condition
Numerator Source	Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart) http://www.hscic.gov.uk/sus
Denominator	Age/Sex Standardised Population. Rate= (Numerator/Denominator) * 100000

Secondary User Services Extract Mart (SUS SEM) data is used.

Only patients with a mandatory tariff recorded have been selected.

The fields that were pulled from SUS SEM include:

- CCG code (based on the GP practice code)
- Sex (this field is used for age/sex standardisation)
- Age_Quinary (Age Band)
- Number of spells

The data does not include CCGs which were not found in the official list of CCGs across England.

Age_Quinary field is presented in 5-year age bands (0-4, 5-9, 10-14, etc.) including the “85+” age band for people aged 85 and over. This field is used for age/sex standardisation.

Number of spells field counts all the day case admissions in 2014/15 and groups into each age band.

The number of day case admissions were suppressed where it was less than or equal to 5 at CCG level.

Emergency admissions indicators

94

Analysis	Emergency admissions analysis
Time Period	2014/15
Age Group	Children: 0 – 18 Adults: 19 - 120
Admissions method	Emergency - 21, 22, 23, 24, 25, 28, 2A, 2B, 2C, 2D
Patient Classification	1
Sex	1, 2
Coding scheme used	Programme Budget Category (PBC), ICD10
Numerator	Number of emergency admissions based on PBC/condition
Numerator Source	Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart) http://www.hscic.gov.uk/sus
Denominator	Age/Sex Standardised Population. Rate= (Numerator/Denominator) * 100000

Secondary User Services Extract Mart (SUS SEM) data is used.
Only patients with a mandatory tariff recorded have been selected.

The fields that were pulled from SUS SEM include:

- CCG code (based on the GP practice code)
- Sex (this field is used for age/sex standardisation)
- Age_Quinary (Age Band)
- Number of spells

The data does not include CCGs which were not found in the official list of CCGs across England.

Age_Quinary field is presented in 5-year age bands (0-4, 5-9, 10-14, etc.) including the “85+” age band for people aged 85 and over. This field is used for age/sex standardisation.

Number of spells field counts all the emergency admissions in the financial year 2014/15 and groups into each age band.

The number of emergency admissions were suppressed where it was less than or equal to 5 at CCG level.

Length of stay indicators

95

Analysis	Length of Stay analysis
Time Period	2014/15
Age Group	0 - 120
Admissions method	Elective - 11, 12, 13 Emergency - 21, 22, 23, 24, 25, 28, 2A, 2B, 2C, 2D
Patient Classification	1
Sex	1, 2
Coding scheme used	Programme Budget Category (PBC), ICD10
Numerator	Total number of bed days for elective/emergency admissions based on PBC/condition (not including day cases)
Numerator Source	Temporary National Repository – Hospital Admissions Databases, SUSSEM (Secondary User Services Extract Mart) http://www.hscic.gov.uk/sus
Denominator	Total number of elective/emergency admissions not including day cases based on PBC/condition.

Secondary User Services Extract Mart (SUS SEM) data is used. Length of Stay data have been extracted at record level.
Only patients with a mandatory tariff recorded have been selected.
Data filtered by Length of Stay less than 180 days.

The fields that were pulled from SUS SEM include:

- APCS_Ident
- CCG code (based on the GP practice code)
- Spell_LoS (Length of Stay)

The data does not include CCGs which were not found in the official list of CCGs across England.

APCS_Ident field was later used to count the number of elective/emergency admissions since the data was extracted at record level.
Spell_LoS field is the spell length of stay derived using Admission Date and Discharge Date.

Standard deviation has been calculated for each CCG in order to calculate confidence intervals using record level data. Length of Stay data was then grouped by CCG to get the total number of bed days (Sum of Spell_LoS field) and total number of elective/emergency admissions (count of APCS_Ident field) for each CCG.

The number of elective/emergency admissions were suppressed where it was less than or equal to 5 at CCG level.

Procedures spend and activity indicators

96

Analysis	Procedures spend and activity analysis
Time Period	2014/15
Age Group	0 – 120
Admissions method	11, 12, 13, 21, 22, 23, 24, 25, 28, 2A, 2B, 2C, 2D, 31, 32, 81, 82, 83
Patient Classification	1, 2
Sex	1, 2
Coding scheme used	Programme Budget Category (PBC), OPCS
Numerator	Total spend on discharges based on PBC and procedures
Numerator Source	Temporary National Repository – Hospital Admissions Databases, SUS SEM (Secondary User Services Extract Mart) http://www.hscic.gov.uk/sus
Denominator	Age/Sex Standardised Population. Rate= (Numerator/Denominator) * 1000

Secondary User Services Extract Mart (SUS SEM) data is used.
Only patients with a mandatory tariff recorded have been selected.

For these indicators, spend on a procedure is the total cost of all spells where the procedure listed is the primary procedure in the spell, and where the primary diagnosis for the spell falls under the programme budget category listed. The figure for “How different are we?” converts the CCG’s spending rate above the benchmark spending rate into the equivalent number of procedures.

The fields that were pulled from SUS SEM for spend on procedures include:

- CCG code (based on the GP practice code)
- Sex (this field is used for age/sex standardisation)
- Age_Quinary (Age Band)
- Number of spells
- Net_SLA_Payment (the cost before MFF is applied)

The data does not include CCGs which were not found in the official list of CCGs across England.

Age_Quinary field is presented in 5-year age bands (0-4, 5-9, 10-14, etc.) including the “85+” age band for people aged 85 and over. This field is used for age/sex standardisation.

Number of spells field counts all the patients admitted to hospital for a procedure and discharged in the financial year 2014/15 and groups into each age band. [Patients admitted in 2014/15 but not discharged until 2015/16 will not count towards the spend. A small number of patients admitted in 2013/14 but not discharged until 2014/15 will count towards the spend for 2014/15.]

Net_SLA_Payment field is the cost before Market Forces Factor (MFF) is applied. This field gives spend on discharges for all patients in the age band in 2014/15.

The fields that were pulled from SUS SEM for procedures activity include:

- CCG code (based on the GP practice code)
- Number of spells (count s all admissions in 2014/15 and groups by CCG).

The number of admissions/discharges were suppressed where it was less than or equal to 5 at CCG level.

Prescribing spend indicators

97

Analysis	Prescribing Spend
Time period	January 2015 - December 2015
Numerator	Net Ingredient cost (NIC) of BNF Chemical Substance Net Ingredient cost (NIC) is the basic price of a drug as stated in Part II Clause 8 of the Drug Tariff
Numerator Source	ePACT.net – data provided by the NHS Business Services Authority
Denominator	CCG ASTRO-PU weighted population Age, Sex and Temporary Resident Originated Prescribing Units
Rate	Numerator / Denominator x 1000 (spend rate per 1,000 ASTRO-PU weighted population)

We have presented a range of indicators grouping a selection of BNF chemical substances together and aggregating the total Net Ingredient cost. We have also presented individual BNF chemical spend indicators where the total spend is large enough and where advised by national clinical leads. The indicators have been standardised using the ASTRO-PU weightings and are shown per 1,000 ASTRO-PU population to allow fair comparison between CCGs.

Net Ingredient cost (NIC) is the basic price of a drug as stated in Part II Clause 8 of the Drug Tariff.

ASTRO-PU (Age, Sex and Temporary Resident Originated Prescribing Units) weightings have been used to weight the CCG population for age and sex to allow for better comparison of prescribing patterns. Further information regarding ASTRO-PU populations and other prescribing specific populations can be found at <http://www.hscic.gov.uk/prescribing/measures>

Annex C: Methodology

How has the potential opportunity been calculated?

99

The potential opportunity highlights the scale of change that would be achieved if the CCG Value moved to the Benchmark Value of the average of the 'Best 5' or 'Lowest 5' CCGs in its group of similar 10 CCGs.

Generally, where a high CCG Value is considered 'worse' then it is calculated using the formula:

Potential Opportunity = (CCG Value – Benchmark Value) * Denominator

The denominator is the most suitable population data for that indicator eg CCG registered population, CCG weighted population, CCG patients on disease register etc. The denominator is also scaled to match the Value. So if the CCG Value and Benchmark Value are given in "per 1,000 population" then the denominator is expressed in thousands, ie 12,000 becomes 12.

For procedures, the potential opportunity can be expressed in pounds, or by dividing by this by the unit cost then it can be expressed in the equivalent number of procedures.